LAURUSLABS

Technical Analysis (Daily Chart) Trend: The stock has been in a strong uptrend since early June, rallying from ~₹600 to above ₹920 before a recent pullback. Price Action: Currently consolidating after a steep rise; trading above 20, 50, 100, and 200 DMA → bullish structure intact. Pullback found support near the 20-day EMA (~₹835) and bounced. Indicators: Parabolic SAR: Now below price → short-term bullish momentum resuming. MACD: Still in positive territory, though momentum is slightly cooling. RSI (60): Healthy zone, showing there’s still room for upside before overbought levels. Key Levels: Support: ₹835, ₹800. Resistance: ₹880, ₹920 (recent top). Technical Bias: Short-term bullish; if it sustains above ₹880, it can retest ₹920–₹940 levels. Upcoming Events & Potential Impact Quarterly Earnings: Strong results with improved guidance could trigger fresh highs. New Facility Approvals: Any green signal from USFDA or EU regulators will be a major positive. M&A Activity: Acquisition of niche capabilities can drive growth. Impact of Tariffs or Geopolitical News Yes — global trade and geopolitics can impact Laurus Labs: Tariff Changes: Import/export duty changes on APIs or pharma goods can influence cost structures. Geopolitical Tensions: Supply chain disruptions from China (key raw material source) or shipping delays can temporarily affect operations. Global Health Crises: Can spike demand for certain drugs, boosting short-term revenue. Portfolio View Short-Term: Positive bias above ₹835; potential retest of ₹920 if momentum holds. Long-Term: Strong fundamentals and sector tailwinds make it a good candidate for accumulation on dips.